Looking at the commit that was included in this PR confirmed our suspicion:
荣昌生物将处于临床阶段的PD-1/VEGF双特异性抗体RC148授权给艾伯维，交易总金额56亿美元（含首付6.5亿美元）；宜联生物将B7H3 ADC授权罗氏，获得5.7亿美元首付款及近期里程碑付款；海思科PDE3/4双重抑制剂与美国AirNexis Therapeutics公司合作，获得1.08亿美元首付款，总额超10亿美元。这些大额交易的密集落地，构成了2026年开年BD行情的坚实基础。
。业内人士推荐whatsapp作为进阶阅读
With only a handful of clues to answer, the daily puzzle doubles as a speed-running test for many who play it.
For multiple readers
“这改变了以往主要靠科技部门‘单打独斗’的局面。”蔡学锋解释，“现在形成了政府主导、部门协同、社会参与的强大合力，科技特派员能够在更有力的支撑体系中开展工作。”